On Wednesday, Moderna (NASDAQ:MRNA)'s stock maintained its Buy rating and $180.00 stock price target according to a recent analysis by a Jefferies financial firm. The firm's assessment focused on Moderna's performance of its RSV (respiratory syncytial virus) vaccine, as presented at the Advisory Committee on Immunization Practices (ACIP).
The vaccine efficacy (VE) over an 18-month period was approximately 50%, aligning with previous expectations set by the firm.
The data showcased at the ACIP revealed that the efficacy of Moderna's RSV vaccine in its second season was below 50%, while the first season alone demonstrated a higher efficacy of 64%. When averaged across an 18-month period, the efficacy settled at around 50% for a single injection. This outcome is consistent with the firm's earlier communications regarding the vaccine's performance.
Moderna conducted its Phase III trials during a season with a high rate of infection, which is not directly comparable to other vaccines like those developed by GSK due to differences in the severity of the seasons during which they were tested. Despite these differences, the observed trend in vaccine efficacy, which tends to decrease by about 2% per month, appeared similar to that of other vaccines.
The Jefferies firm's reiteration of the Buy rating and price target suggests confidence in Moderna's stock, based on the presented RSV vaccine data. The firm's commentary indicates that the results were anticipated and are in line with the natural progression of vaccine efficacy over time.
The stability of Moderna's stock rating and price target reflects the company's ongoing research and development efforts, particularly in the field of vaccines. The data from the ACIP presentation reinforces the company's position in the market and the potential of its RSV vaccine.
In other recent news, Moderna has seen several significant developments. The U.S. Food and Drug Administration (FDA) approved Moderna's mRESVIA, an mRNA respiratory syncytial virus (RSV) vaccine for adults aged 60 and over.
This approval marks the first mRNA vaccine approved for a disease other than COVID-19. Argus has increased its price target on Moderna shares to $150, maintaining a Buy rating. TD Cowen has maintained a Hold rating on Moderna shares with a consistent price target of $75.00.
Moderna's mRNA-1283 vaccine has demonstrated success in its Phase 3 trial, meeting its primary efficacy endpoint. Furthermore, Moderna's investigational mRNA-1083 vaccine, designed to target both influenza and COVID-19, achieved its primary endpoints in a Phase 3 trial, outperforming standard flu and COVID-19 vaccines in adults aged 50 and above.
Jefferies reiterated a Buy rating on Moderna shares with a price target of $180. RBC Capital Markets upgraded Moderna's shares following the FDA approval of the company's Respiratory Syncytial Virus (RSV) vaccine, mRESVIA.
Moderna has reported that its investigational mRNA-1083 vaccine, designed to target both influenza and COVID-19, has achieved its primary endpoints in a Phase 3 trial. The vaccine elicited stronger immune responses compared to the currently licensed flu and COVID-19 vaccines in adults aged 50 and above.
Moderna, Pfizer (NYSE:PFE), BioNTech (NASDAQ:BNTX), and Novavax (NASDAQ:NVAX) have presented promising results for their updated COVID-19 vaccines, which have shown increased efficacy against new strains like KP.2. Moderna's efforts to innovate in the vaccine space could have significant implications for public health, especially in the context of an aging global population and the ongoing management of Covid-19.
InvestingPro Insights
As Moderna continues to develop its RSV vaccine, the financial health and market performance of the company remain critical for investors. According to real-time data from InvestingPro, Moderna holds a market capitalization of $50.02 billion, which underscores the company's significant presence in the biotechnology sector.
Despite a notable decline in revenue over the last twelve months as of Q1 2024, with a decrease of 65.78%, the company's stock has experienced a strong return of 28.11% over the last three months, indicating a positive investor sentiment in the short term.
An InvestingPro Tip worth mentioning is that Moderna holds more cash than debt on its balance sheet, which may provide the company with financial flexibility to navigate through its current challenges, including the anticipated sales decline in the current year. Moreover, the company's liquid assets exceed short-term obligations, which could be a reassuring sign for investors concerned about the company's ability to meet its immediate financial commitments.
For those seeking further insights, there are additional InvestingPro Tips available, which cover various facets of Moderna's financial performance and stock behavior. Interested readers can utilize the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription for more detailed analysis and tips.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.